Why is Dave Denton leaving his position as CFO of Pfizer?

Dave Denton is stepping down to take on a professional opportunity outside of the pharmaceutical industry, specifically in the consumer goods sector. Pfizer has clarified that his departure is voluntary and not related to any performance issues or disagreements with the company.

Who will replace Dave Denton as CFO?

Cecile Guegan, currently Senior Vice President of Finance for the Global Biopharmaceutical Business, has been appointed as the Interim Chief Financial Officer. She will assume this role on August 16, 2026, while Pfizer conducts a search for a permanent successor.

Has Pfizer initiated a search for a new permanent CFO?

Yes, Pfizer has announced that it is conducting a comprehensive process to identify Mr. Denton's successor. An interim CFO is in place to ensure continuity during this search period.

What is the significance of the CFO transition for investors?

A change in CFO can be significant as the role is crucial for financial strategy, reporting, and investor relations. While Pfizer has assured that the departure is not due to performance issues, investors will likely monitor the interim CFO's leadership and the eventual permanent appointment for insights into the company's financial direction and stability.

PFE 8-K: Leadership Changes

Summary

Pfizer Inc. (PFE) has filed an 8-K report announcing a significant leadership change within its finance department. Effective August 15, 2026, Chief Financial Officer Dave Denton will step down to pursue an opportunity in the consumer goods sector. The company has emphasized that Mr. Denton's departure is voluntary and not due to any disagreements or concerns regarding Pfizer's financial performance, operations, or accounting practices. In light of Mr. Denton's departure, Pfizer has appointed Cecile Guegan, currently Senior Vice President of Finance, Global Biopharmaceutical Business, as Interim Chief Financial Officer, effective August 16, 2026. Ms. Guegan, a long-standing Pfizer employee since 2005 with extensive experience in various finance leadership roles within the company, will oversee the CFO responsibilities while a thorough search for a permanent successor is conducted. This transition is a key event for investors to monitor as it may impact financial strategy and investor relations.

Key Highlights

1Chief Financial Officer Dave Denton is stepping down from his role, effective August 15, 2026.
2Mr. Denton is leaving Pfizer to pursue a career opportunity outside the pharmaceutical industry in consumer goods.
3Pfizer states Mr. Denton's departure is not related to the company's financial or operating results.
4The company also confirmed the departure is not due to any disagreements regarding financial, operational, accounting, or reporting policies.
5Cecile Guegan, Senior Vice President, Finance, Global Biopharmaceutical Business, will serve as Interim Chief Financial Officer starting August 16, 2026.
6Ms. Guegan has been with Pfizer since 2005 and has held various finance leadership positions within the company.
7Pfizer is commencing a comprehensive search process to identify a permanent successor for the CFO position.

PFIZER INC 8-K Report, Executive Changes (Jun 18, 2026)

Summary

Key Highlights

Frequently Asked Questions